rivastigmine has been researched along with Age-Related Osteoporosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, C; Inderjeeth, CA; Li, S; Liu, L; Teguh, D; Wu, D; Xu, J; Yuan, J | 1 |
| Abdel-Hafez, S; Abdelzaher, WY; Ali, DM | 1 |
2 other study(ies) available for rivastigmine and Age-Related Osteoporosis
| Article | Year |
|---|---|
Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption.
Topics: Acetylcholinesterase; Animals; Bone Resorption; Cell Differentiation; Cholinesterase Inhibitors; Donepezil; Female; Humans; Mice; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; RANK Ligand; Rivastigmine; Transcription Factors; X-Ray Microtomography | 2023 |
Evaluation of the rivastigmine role against botulinum toxin-A-induced osteoporosis in albino rats: A biochemical, histological, and immunohistochemical study.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Botulinum Toxins, Type A; Calcium; Cholinesterase Inhibitors; Femur; Glutathione; Malondialdehyde; Osteoporosis; Rats, Wistar; Rivastigmine | 2018 |